Racing Biotech's Commoditization Clock
Most genomics, combinatorial chemistry, and other biotech service businesses have been slow to provide clients the anticipated value, either in targets or compounds. Meanwhile, their competitors have caught up, commoditizing the technologies of even the industry leaders. With this lesson in mind, a new group of start-ups, pursuing "validated target discovery" technologies and the possibility of much faster timelines to targets and compounds, is racing to snare high-value partnerships while their technologies still have unique value. The partnerships won't leave all the chemistry and preclinical work to the clients--the low-risk strategy platform companies used to pursue--but will instead pay enough money so that the new start-ups, like Rigel and Arcaris, can create fully-integrated drug discovery platforms capable of producing IND-stage products. These start-ups need to take on the added risk in order to generate the required upside and create the only kind of enduring, high-value intellectual property in the drug industry: products themselves.
You may also be interested in...
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.
FDA releases information about reporting results of OTC at-home COVID-19 antigen tests, as well as recommendations on who should get tested, when and how often.